Shamik J. Parikh
About Shamik J. Parikh
Humacyte’s Chief Medical Officer since April 2022, age 52 in 2025, with a medical degree from Topiwala National Medical College, residency in internal medicine/pediatrics at St. Joseph Mercy Oakland, and a post‑doctoral fellowship in clinical endocrinology at NIH/NICHD; earlier service includes Lieutenant Commander in the U.S. Public Health Service . Prior to Humacyte, Parikh was Vice President & Head of the Patient Safety Center for Excellence at AstraZeneca (2016–2022), VP Global Medical Affairs for CVRM (2012–2016), and led clinical development roles at AstraZeneca (2005–2012) and GSK (2003–2005) . Company performance context during his tenure includes the commercial launch of Symvess in 2025 and initial product revenues of $0.7M in Q3 2025 vs $0 in Q3 2024, while nine‑month 2025 net loss narrowed to $16.0M vs $127.8M in 2024 due to non‑cash fair value gains and early commercialization .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| AstraZeneca | VP & Head, Patient Safety Center for Excellence | 2016–2022 | Led enterprise patient safety; member of Executive Safety Board, shaping global risk management . |
| AstraZeneca | VP, Global Medical Affairs – Cardiovascular, Renal & Metabolism (CVRM) | 2012–2016 | Drove medical strategy supporting CVRM portfolio and launches . |
| AstraZeneca | Director/Senior Director/Executive Director, Clinical Development – Cardiovascular & Metabolics | 2005–2012 | Led clinical programs advancing CV/metabolic assets through development . |
| GlaxoSmithKline | Director, U.S. Clinical Development & Medical Affairs | 2003–2005 | Directed U.S. clinical development/medical affairs activities . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| NIH/NICHD | Clinical Investigator | Early career | Conducted endocrine clinical research; foundation for translational leadership . |
| U.S. Public Health Service | Lieutenant Commander | Early career | Public service and health systems leadership experience . |
Fixed Compensation
- Not disclosed in the 2025 proxy’s Named Executive Officer (NEO) Summary Compensation Table; NEOs for 2024 were CEO, CFO, COO (Parikh not included) .
Performance Compensation
- Company program: cash bonuses based on corporate/individual objectives, with determinations by the Compensation Committee; equity compensation primarily stock options with vesting 25% at year 1 then monthly over 36 months; change‑in‑control provisions provide accelerated vesting upon certain involuntary terminations post‑transaction; no formal executive equity ownership guidelines .
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Rule 10b5‑1 trading plan | Adopted August 16, 2024; first possible trade Nov 21, 2024; terminates upon completion or Aug 25, 2025; provides for sale of up to 181,512 shares, indicating scheduled selling over the plan period . |
| Anti‑hedging & pledging policy | Hedging and short sales prohibited; options transactions only via company grants; pledging of company securities not permitted without prior Board approval . |
| Stock ownership guidelines | No formal equity ownership guidelines for executives; equity awards primarily options granted at hire/periodically . |
| Beneficial ownership disclosure | Parikh not individually listed in 2024/2025 beneficial ownership tables; the tables enumerate certain executives/directors and >5% holders . |
Employment Terms
- Role start date: April 2022 (Chief Medical Officer). Specific employment agreement terms (salary, target bonus, severance, change‑of‑control) for Parikh are not disclosed in the proxy; agreements and severance terms are detailed for CEO, CFO, COO only .
Performance & Track Record
- Clinical impact: Parikh publicly highlighted outcomes from a subgroup in the pivotal V005 Phase 2/3 study—11/12 patients retained secondary patency (92%), no amputations, zero confirmed conduit infections; positioned Symvess for limb salvage in iatrogenic vascular injury settings .
- Commercialization: 2025 launch of Symvess; Q3 2025 product revenue $703K and total revenue $753K vs $0 in Q3 2024; nine‑month 2025 total revenue $1.571M and net loss narrowed to $16.0M (vs $127.8M in 2024) on fair value gains and early revenue; SG&A increased with commercialization .
Company Performance Context (recent quarters)
| Metric | Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|
| Total Revenue ($000s) | $0 | $0 | $301 | $753 |
| Product Revenue ($000s) | $0 | $0 | $100 | $703 |
| Net Income (Loss) ($000s) | $(56,663) | $(39,202) | $(37,658) | $(17,510) |
Governance & Incentive Controls
- Compensation Committee uses independent consultant (Radford/Aon) for benchmarking; committee assessed and confirmed consultant independence and conducts annual compensation risk assessment .
- Compensation Clawback Policy adopted September 14, 2023, compliant with Exchange Act Section 10D/Nasdaq; requires recoupment of incentive‑based comp upon an accounting restatement within a three‑year look‑back .
Compensation Committee Analysis
- Mix of pay elements balances short/long‑term goals; independent consultant engagement; base salaries reviewed annually; bonuses based on objectives; equity grants typically in December/January; no timing around MNPI releases; company relies on options rather than RSUs, implying greater “at‑risk” equity value tied to future stock performance .
Risk Indicators & Red Flags
- Insider selling pressure: Parikh’s Rule 10b5‑1 plan authorizes up to 181,512 shares for sale through Aug 2025, indicating structured supply to the market; plan adoption reduces insider trading risk by providing affirmative defense .
- Anti‑hedging/pledging: Robust prohibitions reduce misalignment risks; pledging requires Board approval, mitigating collateralization risks .
- Litigation environment: Multiple shareholder lawsuit announcements/public notices in Jan 2025, reflecting heightened scrutiny; company disclosures continue despite this backdrop .
Investment Implications
- Alignment and retention: Lack of Parikh‑specific compensation disclosure reduces transparency on pay‑for‑performance linkage; however, company‑wide use of options and clawback policy provides at‑risk and accountability mechanisms .
- Near‑term trading dynamics: The 10b5‑1 plan introduces potential selling flow through Aug 2025; monitor Form 4 filings and plan executions for actual volumes and cadence .
- Execution track record: Clinical outcomes and initial commercialization of Symvess are constructive; revenue remains nascent, and operating losses persist as commercialization scales—focus on regulatory/manufacturing execution metrics that likely underpin bonus objectives for executives .
- Governance posture: Independent compensation oversight, anti‑hedging/pledging, and clawback policy mitigate governance risk; continued absence of formal ownership guidelines means alignment relies on option design and individual holdings .